pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
sniff results

“Oncology”

482 total hits · 4 drugs · 36 companies · 0 diseases · 342 catalysts · 100 news

Drugs(4)

expand →
Preclinical
Drugs for Oncology
Pancreatic Ductal Adenocarcinoma
Phase 1
Gene Therapy to Target CD22 for Oncology
B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Preclinical
Immuno-oncology
Breast Cancer
Phase 1
Peptide to Inhibit CD200 for Oncology
Recurrent Glioblastoma Multiforme (GBM)

🐶 Companies(36)

expand →
  • $TOIOncology Institute, Inc.
  • $TOIIWOncology Institute, Inc.
  • $DFPHOncology Institute, Inc.
  • Oncology Pharma Inc
  • $ALXOALX ONCOLOGY HOLDINGS INC
  • $AKTSAktis Oncology, Inc.
  • Beijing zhikangbo Medical Oncology Research Co Ltd
  • $BBOTBridgeBio Oncology Therapeutics, Inc.

Catalysts(342)

expand →
view all 342 catalyst results →

News(100)

expand →
  • Assessing Merck and Moderna’s mRNA cancer vaccine↗
    On this week's “The Readout LOUD,” we discuss the latest cancer data presented at the annual meeting of the European Society for Medical Oncology.
    stat · 8h ago
  • R&D chief Dean Li says Merck outflanked rivals with its sac-TMT cancer program↗
    Merck's R&D head Dean Li believes he’s outfoxed his competition for the next generation of oncology drugs, jumping into a wide set of indications that could help it expand the potential of its anti…
    endpoints · 1d ago
  • Astellas bets up to $1.34B for option to advance Audax immuno-oncology asset↗
    Astellas Pharma could secure the exclusive global rights to Audax Biosciences’ DAX-044, an antibody-cytokine fusion therapy that activates the immune system in the vicinity of the tumor.
    biospace · 2d ago
view all 36 company results →
Astellas buys option on preclinical IL-12 cancer drug from Audax Biosciences↗
Astellas has taken an exclusive option to license a preclinical immuno-oncology asset from Australian biotech Audax Biosciences. The deal features $285 million that covers the upfront fee and a pay…
endpoints · 2d ago
  • Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025↗
    Merck stole the show at the European Society for Medical Oncology (ESMO) annual conference, with new data on its Moderna-partnered personalized cancer vaccine leaking prior to the presentation and…
    biospace · 2d ago
  • Astellas makes $1.3B bet on Audax’s preclinical push to reverse decades of IL-12 woes↗
    Astellas has struck a deal for Audax Biosciences’ IL-12 program, committing up to $285 million in upfront and option fees to secure a chance to license the preclinical immuno-oncology program.
    fiercebiotech · 2d ago
  • STAT+: GSK sees its return to cancer start to pay off↗
    A decade ago, GSK was out of oncology. It could soon pick up approval for its sixth cancer drug.
    stat · 4d ago
  • Beyond cancer vaccine, how did Merck’s oncology pipeline do at #ESMO26?↗
    MADRID — Much of the coverage on Merck at the European Society for Medical Oncology congress centered on its Moderna-partnered cancer vaccine trial. But the company is actually at the meeting with…
    endpoints · 4d ago
  • view all 100 news results →
    Nov 1, 2031
    phase readout
    in 5y
    Phase 3 primary completion: Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
    →
    Jun 1, 2030
    phase readout
    in 4y
    Phase 2 primary completion: Local and Systemic Immune Modulation by Rilvegostomig (AZD2936) in the Treatment of Advanced Gastric Cancer (RILVE Project)
    →
    Mar 1, 2030
    phase readout
    in 3y
    Phase 2 primary completion: DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
    →
    Jan 1, 2030
    phase readout
    in 3y
    Trial primary completion: MELanoma Brain Metastasis Treated With CYberknife
    →
    Dec 1, 2029
    phase readout
    in 3y
    Trial primary completion: Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients
    →
    Sep 30, 2029
    phase readout
    in 3y
    Trial primary completion: Structured Cardio-Oncology Rehabilitation for Cardiovascular Outcomes in Cancer Survivors
    →
    Jan 15, 2029
    phase readout
    in 2y
    Phase 3 primary completion: The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
    →
    Nov 1, 2028
    phase readout
    in 2y
    Phase 1 primary completion: A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
    →